HHS may reconsider 2022 Medicare premiums after cost cut for Alzheimer’s drug
Posted On: Jan. 11, 2022 10:00 AM CSTBiogen’s decision to halve the price of its controversial Alzheimer’s drug Aduhelm has the Biden administration rethinking the 15% hike for Medicare Part B premiums for 2022, Fierce Healthcare reports. Department of Health and Human Services Secretary Xavier Becerra announced Jan. 10 that he wants the Centers for Medicare and Medicaid Services to reassess its proposed price hike, which was based on an expected rise in drug costs, especially Aduhelm.